Published in Cancer Weekly, January 9th, 2007
The trial is an investigator sponsored trial, designed and led by Krefklinikken, Rigshospital-Radiumhospitalet in Olso in collaboration with St. Olav's Hospital in Trondheim. Pharmexa has agreed to supply GV1001 for the trial, which is partly funded by Norges Forskningsred (the Norwegian Research Council).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.